New Century Financial Group LLC Purchases Shares of 1,135 Axon Enterprise, Inc. (NASDAQ:AXON)

New Century Financial Group LLC acquired a new position in Axon Enterprise, Inc. (NASDAQ:AXON) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,135 shares of the biotechnology company’s stock, valued at approximately $334,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Avantax Advisory Services Inc. raised its position in Axon Enterprise by 0.8% in the first quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock worth $1,659,000 after acquiring an additional 40 shares during the period. GSA Capital Partners LLP bought a new stake in shares of Axon Enterprise during the 1st quarter valued at $931,000. Sumitomo Mitsui Trust Holdings Inc. increased its stake in shares of Axon Enterprise by 14.8% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company’s stock worth $53,307,000 after purchasing an additional 22,013 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in Axon Enterprise by 21.7% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,153 shares of the biotechnology company’s stock worth $2,693,000 after purchasing an additional 1,634 shares during the period. Finally, Cim LLC purchased a new position in Axon Enterprise during the fourth quarter valued at $1,409,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the company. Craig Hallum upped their price target on Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Northland Securities increased their target price on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a report on Thursday, August 8th. Barclays increased their price objective on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Robert W. Baird increased their price target on Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 10th. Finally, JMP Securities raised their price target on Axon Enterprise from $375.00 to $430.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $365.38.

Insider Buying and Selling

In other news, Director Jeri Williams sold 110 shares of the firm’s stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $400.00, for a total value of $44,000.00. Following the completion of the sale, the director now directly owns 1,934 shares of the company’s stock, valued at approximately $773,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Julie A. Cullivan sold 900 shares of the firm’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $353.53, for a total value of $318,177.00. Following the completion of the sale, the director now owns 3,653 shares in the company, valued at approximately $1,291,445.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeri Williams sold 110 shares of the company’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $400.00, for a total transaction of $44,000.00. Following the transaction, the director now owns 1,934 shares in the company, valued at $773,600. The disclosure for this sale can be found here. Over the last quarter, insiders sold 318,091 shares of company stock worth $115,706,734. Corporate insiders own 6.10% of the company’s stock.

Axon Enterprise Stock Performance

NASDAQ:AXON opened at $399.22 on Wednesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The company has a market cap of $30.13 billion, a price-to-earnings ratio of 116.73, a PEG ratio of 10.59 and a beta of 0.94. Axon Enterprise, Inc. has a 1 year low of $190.01 and a 1 year high of $400.78. The stock’s 50 day simple moving average is $359.52 and its two-hundred day simple moving average is $321.46.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The business had revenue of $504.00 million during the quarter, compared to analyst estimates of $478.35 million. During the same quarter last year, the business earned $0.80 earnings per share. Axon Enterprise’s quarterly revenue was up 34.5% compared to the same quarter last year. As a group, equities analysts anticipate that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.